These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 30210037)

  • 1. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.
    Vrankar M; Stanic K
    Radiol Oncol; 2018 Feb; 52(3):281-288. PubMed ID: 30210037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy.
    Vrankar M; Zwitter M; Kern I; Stanic K
    Neoplasma; 2018; 65(1):140-146. PubMed ID: 29322798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
    Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
    Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
    Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
    Vrankar M; Kern I; Stanic K
    Radiat Oncol; 2020 Oct; 15(1):247. PubMed ID: 33121520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
    Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K
    Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of K
    Wang D; Liu S; Fu J; Zhang P; Zheng S; Qiu B; Liu H; Ye Y; Guo J; Zhou Y; Jiang H; Yin S; He H; Xie C; Liu H
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38910009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
    Gerber DE; Urbanic JJ; Langer C; Hu C; Chang IF; Lu B; Movsas B; Jeraj R; Curran WJ; Bradley JD
    Clin Lung Cancer; 2017 May; 18(3):333-339. PubMed ID: 27923550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy].
    Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339
    [No Abstract]   [Full Text] [Related]  

  • 17. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
    Filippi AR; Bar J; Chouaid C; Christoph DC; Field JK; Fietkau R; Garassino MC; Garrido P; Haakensen VD; Kao S; Markman B; McDonald F; Mornex F; Moskovitz M; Peters S; Sibille A; Siva S; van den Heuvel M; Vercauter P; Anand S; Chander P; Licour M; de Lima AR; Qiao Y; Girard N
    ESMO Open; 2024 Jun; 9(6):103464. PubMed ID: 38833971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
    Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.